Costs and Complications of Respiratory Syncytial Virus and Acute Respiratory Infections in the Adult Population: Analysis of a German Claims Database

Pavo Marijic (), Roman Kliemt, Martin Krammer, Nikolaus Kolb, Theo Last, Andreas Ambrosch, Santiago Ewig, Rembert Koczulla, Jörg Schelling, Claus Vogelmeier, Maria Waize, Manuela Stierl, Maria João Fonseca, Sara Pedron and Alen Marijam
Additional contact information
Pavo Marijic: GSK
Roman Kliemt: WIG2 Scientific Institute for Health Economics and Health System Research
Martin Krammer: GSK
Nikolaus Kolb: ZEG Berlin – Center for Epidemiology and Health Research
Theo Last: GSK
Andreas Ambrosch: Hospital of the Merciful Brothers
Santiago Ewig: Thoraxzentrum Ruhrgebiet, EVK Herne and Augusta-Kranken-Anstalt Bochum
Rembert Koczulla: Schoen Klinik Berchtesgadener Land
Jörg Schelling: Hausärztliche Gemeinschaftspraxis Martinsried
Claus Vogelmeier: University of Marburg
Maria Waize: GSK
Manuela Stierl: GSK
Maria João Fonseca: GSK
Sara Pedron: GSK
Alen Marijam: GSK

PharmacoEconomics - Open, 2025, vol. 9, issue 3, No 10, 445-459

Abstract: Abstract Background Respiratory syncytial virus (RSV) infections pose health and economic burdens to adults. Using claims data, we estimated RSV-associated costs, healthcare resource utilization (HCRU), and complication rates from patients of a nationwide German health insurance database. Methods We analyzed confirmed RSV, RSV-possible, and acute respiratory infection (ARI) cohorts, plus 1:1 matched control cohorts of individuals ≥ 18 years from 2010 to 2019. Matching was performed separately for patients 18–49, 50–59, and ≥ 60 years. Medical costs, HCRU, and sick leave were assessed for inpatients and outpatients. Complications were compared between cases and controls, and logistic regression assessed odds ratios (ORs) for risk. Results Altogether, 2668 confirmed RSV index episodes occurred. In ≥ 60-year-olds, 862 episodes incurred mean excess costs of €3773 (95% confidence interval [CI]: €2956–€4591) per episode during the index quarter and €3286 (95% CI: €1841–€4732) in the following four quarters. Mean costs were €5553 per episode for inpatients and €116 for outpatients. In ≥ 60-year-olds, risk for congestive heart failure hospitalization (OR 2.3; 95% CI: 1.4–3.8), exacerbation of asthma (OR 6.0; 95% CI: 1.7–20.9), and chronic obstructive pulmonary disease (OR 3.9; 95% CI: 2.6–5.8) were higher for confirmed RSV than controls. In younger groups, costs, HCRU, and complications were also higher in cases than controls. The complication frequencies increased with age. RSV-possible episodes incurred mean excess costs of €615 (95% CI: €605–€626) during the index quarter and €610 (95% CI: €583–€637) during the following four quarters, while in the ARI cohort, the excess costs were €1003 (95% CI: €991–€1015) during the index quarter and €1003 (95% CI: €973–€1032) in the following four quarters. For all three cohorts, individuals who had comorbidities, were immunocompromised, or living in long-term care facilities incurred higher costs. Conclusions Confirmed RSV is associated with high excess costs – especially in hospital settings – and HCRU. Complication risk increased with RSV presence. Graphical Abstract

Date: 2025
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s41669-025-00565-3 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:9:y:2025:i:3:d:10.1007_s41669-025-00565-3

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669

DOI: 10.1007/s41669-025-00565-3

Access Statistics for this article

PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell

More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().